| pubmed-article:6193970 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0007806 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0006104 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0036751 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0003286 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0020361 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0243127 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0003299 | lld:lifeskim |
| pubmed-article:6193970 | lifeskim:mentions | umls-concept:C0443331 | lld:lifeskim |
| pubmed-article:6193970 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6193970 | pubmed:dateCreated | 1983-11-23 | lld:pubmed |
| pubmed-article:6193970 | pubmed:abstractText | The effect of antiepileptic drug di-n-propylacetamide (DPM) on 5-hydroxytryptamine (5-HT) turnover in rat brain and 5-hydroxyindoleacetic acid (5-HIAA) in cat cerebrospinal fluid (CSF) was investigated. DPM (200 mg/kg) increased brain 5-HIAA without altering the 5-HT level. DPM augmented the accumulation of 5-HT induced by monoamine oxidase inhibition with pargyline (80 mg/kg) and enhanced the accumulation of 5-HIAA in the brain following blockade of transport of this metabolite by probenecid (200 mg/kg). Prior inhibition of 5-HT synthesis by p-chlorophenylalanine (300 mg/kg) abolished the DPM-induced increase in cerebral 5-HIAA. DPM (100 mg/kg) given daily for 5 days considerably elevated 5-HIAA in the CSF of cat during the treatment period. We conclude that DPM increases the turnover of 5-HT in brain and that this can be observed by monitoring the 5-HIAA content of CSF. | lld:pubmed |
| pubmed-article:6193970 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6193970 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6193970 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6193970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6193970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6193970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6193970 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6193970 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6193970 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:6193970 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:6193970 | pubmed:author | pubmed-author:BulatMM | lld:pubmed |
| pubmed-article:6193970 | pubmed:author | pubmed-author:Markovi?ZZ | lld:pubmed |
| pubmed-article:6193970 | pubmed:author | pubmed-author:SkarpaDD | lld:pubmed |
| pubmed-article:6193970 | pubmed:author | pubmed-author:WhittonP SPS | lld:pubmed |
| pubmed-article:6193970 | pubmed:author | pubmed-author:Oreskovi?DD | lld:pubmed |
| pubmed-article:6193970 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6193970 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:6193970 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:6193970 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6193970 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6193970 | pubmed:pagination | 57-62 | lld:pubmed |
| pubmed-article:6193970 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:meshHeading | pubmed-meshheading:6193970-... | lld:pubmed |
| pubmed-article:6193970 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6193970 | pubmed:articleTitle | Effect of the antiepileptic di-n-propylacetamide on 5-hydroxytryptamine turnover in the brain and 5-hydroxyindoleacetic acid level in the cerebrospinal fluid. | lld:pubmed |
| pubmed-article:6193970 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6193970 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6193970 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6193970 | lld:pubmed |
